Multimodal treatment and immune checkpoint inhibition in sinonasal mucosal melanoma: real-world data of a retrospective, single-center study.
Immune checkpoint inhibition
Immunotherapy
Melanoma
Mutation status
Sinonasal
Surgery
Journal
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
13
01
2023
accepted:
08
05
2023
medline:
31
7
2023
pubmed:
5
6
2023
entrez:
5
6
2023
Statut:
ppublish
Résumé
Local failure and distant metastases occur frequently in sinonasal mucosal melanoma (SNMM). Response rates to chemotherapy are low and targetable mutations are rarely detected. However, there is increasing data indicating efficacy of immune checkpoint inhibition (ICI). The aim of this retrospective monocenter study was to assess the mutational landscape and to evaluate the outcome of surgical treatment and ICI in SNMM in a real-world setting. Thirty-eight SNMM patients being treated between 1999 and 2020 at our institution were retrospectively reviewed. Survival curves were generated according to Kaplan-Meier and compared by the log-rank test. Local failure was seen in 60% of patients treated in a curative intent. Overall, 24% of all patients suffered from regional and 66% from distant metastases. Next generation sequencing revealed mutations of BRAF, NRAS and KRAS. One out of three patients treated with a primary ICI showed a complete response (CR) and two showed progressive disease. Eleven patients received ICI as a palliative treatment. CR could be observed in three patients and stable disease in one patient. In the whole study population, the 5-year overall survival rate (OS) was 26%. OS was better for patients who received ICI during the course of disease. Recurrences and distant metastases are frequent in SNMM. Durable CR could be observed after primary and palliative ICI. Therefore, ICI in a palliative, adjuvant or even neoadjuvant setting might play a promising role in SNMM therapy while targetable mutations are rarely detected.
Identifiants
pubmed: 37272953
doi: 10.1007/s00405-023-08015-8
pii: 10.1007/s00405-023-08015-8
pmc: PMC10382337
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4215-4223Subventions
Organisme : Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg
ID : Z-2/81
Organisme : Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg
ID : Z-2/78
Informations de copyright
© 2023. The Author(s).
Références
Alves IS, Berriel LG, Alves RT et al (2017) Sinonasal melanoma: a case report and literature review. Case Rep Oncol Med 2017:8201301
pubmed: 28255482
pmcid: 5306975
Chang AE, Karnell LH, Menck HR (1998) The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 83(8):1664–1678
pubmed: 9781962
Takata M, Murata H, Saida T (2010) Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma. Pigment Cell Melanoma Res 23(1):64–71
pubmed: 19788535
Newell F, Kong Y, Wilmott JS et al (2019) Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nat Commun 10(1):3163
pubmed: 31320640
pmcid: 6639323
Hayward NK, Wilmott JS, Waddell N et al (2017) Whole-genome landscapes of major melanoma subtypes. Nature 545(7653):175–180
pubmed: 28467829
Papaspyrou G, Garbe C, Schadendorf D, Werner JA, Hauschild A, Egberts F (2011) Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors. Melanoma Res 21(6):475–482
pubmed: 21897303
Furney SJ, Turajlic S, Stamp G et al (2013) Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J Pathol 230(3):261–269
pubmed: 23620124
Lengyel E, Gilde K, Remenar E, Esik O (2003) Malignant mucosal melanoma of the head and neck. Pathol Oncol Res 9(1):7–12
pubmed: 12704440
Lian B, Cui CL, Zhou L et al (2017) The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients. Ann Oncol 28(4):868–873
pubmed: 28039178
Amit M, Tam S, Abdelmeguid AS et al (2018) Patterns of treatment failure in patients with sinonasal mucosal melanoma. Ann Surg Oncol 25(6):1723–1729
pubmed: 29626308
Lombardi D, Bottazzoli M, Turri-Zanoni M et al (2016) Sinonasal mucosal melanoma: a 12-year experience of 58 cases. Head Neck 38(Suppl 1):E1737–E1745
pubmed: 26676523
Sayed Z, Migliacci JC, Cracchiolo JR et al (2017) Association of surgical approach and margin status with oncologic outcomes following gross total resection for sinonasal melanoma. JAMA Otolaryngol Head Neck Surg 143(12):1220–1227
pubmed: 29049462
pmcid: 5808194
Moreno MA, Roberts DB, Kupferman ME et al (2010) Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson Cancer. Cancer 116(9):2215–2223
pubmed: 20198705
Sahovaler A, Ziai H, Cardemil F et al (2021) Importance of margins, radiotherapy, and systemic therapy in mucosal melanoma of the head and neck. Laryngoscope 131(10):2269–2276
pubmed: 33856051
Seetharamu N, Ott PA, Pavlick AC (2010) Mucosal melanomas: a case-based review of the literature. Oncologist 15(7):772–781
pubmed: 20571149
pmcid: 3228004
Temam S, Mamelle G, Marandas P et al (2005) Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer 103(2):313–319
pubmed: 15578718
Benlyazid A, Thariat J, Temam S et al (2010) Postoperative radiotherapy in head and neck mucosal melanoma: a GETTEC study. Arch Otolaryngol Head Neck Surg 136(12):1219–1225
pubmed: 21173371
Weber JS, D’Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375–384
pubmed: 25795410
Fujimura T, Kambayashi Y, Ohuchi K et al (2020) Successful treatment of a patient with anti-PD1 antibody-resistant advanced mucosal melanoma with nivolumab, ipilimumab plus denosumab combination therapy. Case Rep Oncol 13(1):271–275
pubmed: 32308589
pmcid: 7154272
Ascierto PA, Vanella V, Grimaldi AM et al (2016) Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial. Cancer Immunol Immunother 65(11):1395–1400
pubmed: 27604993
D’Angelo SP, Larkin J, Sosman JA et al (2017) Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol 35(2):226–235
pubmed: 28056206
Schadendorf D, Ascierto PA, Haanen J et al (2019) Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). Eur J Cancer 121:144–153
pubmed: 31581055
Hamid O, Robert C, Ribas A et al (2018) Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer 119(6):670–674
pubmed: 30202085
pmcid: 6173747
Shoushtari AN, Munhoz RR, Kuk D et al (2016) The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer 122(21):3354–3362
pubmed: 27533633
Nishijima TF, Shachar SS, Nyrop KA, Muss HB (2017) Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist 22(4):470–479
pubmed: 28275115
pmcid: 5388381
Ozturk Sari S, Yilmaz I, Taskin OC et al (2017) BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases. Pathology 49(1):55–61
pubmed: 27914687
Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949–954
pubmed: 12068308
Cosgarea I, Ugurel S, Sucker A et al (2017) Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations. Oncotarget 8(25):40683–40692
pubmed: 28380455
pmcid: 5522195
Heppt MV, Roesch A, Weide B et al (2017) Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma. Eur J Cancer 81:36–44
pubmed: 28600969
Lund VJ (2020) Sinonasal malignant melanoma. Adv Otorhinolaryngol 84:185–196
pubmed: 32731237
Ganti A, Raman A, Shay A et al (2020) Treatment modalities in sinonasal mucosal melanoma: a national cancer database analysis. Laryngoscope 130(2):275–282
pubmed: 31021415
Elsamna ST, Ahsanuddin S, Mir GS et al (2021) Surgical margin status and survival following resection of sinonasal mucosal melanoma. Laryngoscope 131(11):2429–2435
pubmed: 33864635
Gore MR, Zanation AM (2012) Survival in sinonasal melanoma: a meta-analysis. J Neurol Surg B Skull Base 73(3):157–162
pubmed: 23730543
pmcid: 3424013
Buchanan DJ, Schlaerth J, Kurosaki T (1998) Primary vaginal melanoma: thirteen-year disease-free survival after wide local excision and review of recent literature. Am J Obstet Gynecol 178(6):1177–1184
pubmed: 9662299
Iddings DM, Fleisig AJ, Chen SL, Faries MB, Morton DL (2010) Practice patterns and outcomes for anorectal melanoma in the USA, reviewing three decades of treatment: is more extensive surgical resection beneficial in all patients? Ann Surg Oncol 17(1):40–44
pubmed: 19774417
Jarrom D, Paleri V, Kerawala C et al (2017) Mucosal melanoma of the upper airways tract mucosal melanoma: a systematic review with meta-analyses of treatment. Head Neck 39(4):819–825
pubmed: 27898196
Liu ZP, Luo JW, Xu GZ et al (2017) Failure patterns and prognostic factors of patients with primary mucosal melanoma of the nasal cavity and paranasal sinuses. Acta Otolaryngol 137(10):1115–1120
pubmed: 28767022
Moya-Plana A, Auperin A, Obongo R et al (2019) Oncologic outcomes, prognostic factor analysis and therapeutic algorithm evaluation of head and neck mucosal melanomas in France. Eur J Cancer 123:1–10
pubmed: 31670075
Low CM, Price DL, Moore EJ et al (2019) Nodal and distant metastases in sinonasal mucosal melanoma: a population-based analysis. Laryngoscope 130(3):622–627
pubmed: 31077407
Lechner M, Takahashi Y, Turri-Zanoni M et al (2022) International multicenter study of clinical outcomes of sinonasal melanoma shows survival benefit for patients treated with immune checkpoint inhibitors and potential improvements to the current TNM staging system. J Neurol Surg B Skull Base. https://doi.org/10.1055/s-0042-1750178
doi: 10.1055/s-0042-1750178
pubmed: 37405239
pmcid: 10317567
Topalian SL, Sznol M, McDermott DF et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020–1030
pubmed: 24590637
pmcid: 4811023
Manolidis S, Donald PJ (1997) Malignant mucosal melanoma of the head and neck: review of the literature and report of 14 patients. Cancer 80(8):1373–1386
pubmed: 9338460
Ascierto PA, Accorona R, Botti G et al (2017) Mucosal melanoma of the head and neck. Crit Rev Oncol Hematol 112:136–152
pubmed: 28325255